Entrada Therapeutics EPS Diluted (Quarterly) Analysis

Entrada Therapeutics Inc (TRDA)

18.05 +0.12 (+0.67%) USD | NASDAQ | Nov 21, 16:00

18.08 +0.02 (+0.14%) After-Hours: 20:00

EPS Diluted (Quarterly) Chart

Historical EPS Diluted (Quarterly) Data

View and export this data back to 2020. Upgrade now.

Date	Value
September 30, 2024	-0.35
June 30, 2024	1.55
March 31, 2024	0.68
December 31, 2023	-0.29
September 30, 2023	1.02
June 30, 2023	-0.78
March 31, 2023	-0.21
December 31, 2022	-0.79
September 30, 2022	-0.80

Date	Value
June 30, 2022	-0.74
March 31, 2022	-0.69
December 31, 2021	-0.89
September 30, 2021	-0.5097
June 30, 2021	-0.4835
March 31, 2021	-0.4093
December 31, 2020	-0.4236
September 30, 2020	-0.3414

Earnings per Share Definition

Earnings per share measures the total net income / average shares outstanding during income period. There are a few variations to earnings per share that are listed including "EPS Basic", "EPS Diluted", "Normalized Basic EPS", and "Normalized Diluted EPS". Each of these metrics are dependent on which earnings and shares outstanding metrics are used. Basic and Diluted EPS differ in that diluted shares are the amount of shares outstanding after all convertible securities, options, and warrants are exercised. Normalized EPS allows does not include one-time expenses.

Read full definition.

EPS Diluted (Quarterly) Range, Past 5 Years

-0.89

Minimum

Dec 2021

1.55

Maximum

Jun 2024

-0.2622

Average

-0.4236

Median

Dec 2020

EPS Diluted (Quarterly) Benchmarks

Catalyst Pharmaceuticals Inc	0.35
Vertex Pharmaceuticals Inc	4.01
Assembly Biosciences Inc	-1.51
Sarepta Therapeutics Inc	0.34
Regenxbio Inc	-1.17

EPS Diluted (Quarterly) Related Metrics

Net Income (Quarterly)	-14.03M
Revenue (Quarterly)	19.57M
Total Expenses (Quarterly)	41.23M
Enterprise Value	226.09M
Profit Margin (Quarterly)	-71.70%
Earnings Yield	8.81%
Operating Earnings Yield	8.87%
Normalized Earnings Yield	8.809